2026-10-27

Qianhong Pharmaceutical said at an earnings briefing that its QHRD106 injection for acute ischemic stroke is in the closing stage of Phase IIb trials. After completing communications with China’s Center for Drug Evaluation (CDE), the company will promptly advance Phase III trials and related marketing-authorization filings.

Qianhong Pharmaceutical said at an earnings briefing that its QHRD106 injection for acute ischemic stroke is in the closing stage of Phase IIb trials. After completing communications with China’s Center for Drug Evaluation (CDE), the company will promptly advance Phase III trials and related marketing-authorization filings.

2026-10-27

China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations

China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations list and barred from participating in national drug procurement for four years; JSC Farmak and its applicant Shanghai Liyi Pharmaceutical Technology Co. were likewise listed and barred for two years.

2026-10-27

Moody's analyst said future rating actions will depend on whether Japan's recent resilience can withstand future shocks.

Moody's analyst said future rating actions will depend on whether Japan's recent resilience can withstand future shocks.

2026-10-27

穆迪分析師：未來評級行動取決於日本最新的韌性能否抵禦未來衝擊。

穆迪分析師：未來評級行動取決於日本最新的韌性能否抵禦未來衝擊。

2026-10-27

MOODY'S sovereign analyst says Japan is showing signs of sustained growth and stable inf.

MOODY'S sovereign analyst says Japan is showing signs of sustained growth and stable inf.

2026-10-27

穆迪主權分析師：日本顯現持續增長和通脹穩定的跡象。

穆迪主權分析師：日本顯現持續增長和通脹穩定的跡象。